Erenumab reduces migraine medication useReduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Study shows significant migraine impact
We explored how erenumab impacts the use of acute headache medication, especially migraine-specific medications (MSM). The study analyzed data from two major clinical trials involving patients with episodic migraine (EM) and chronic migraine (CM). Participants received either erenumab or placebo over a set period, allowing us to compare medication usage accurately.
Our findings indicate that treatment with erenumab led to a significant decrease in the number of days patients used acute headache medications, particularly in those relying on MSM. This reduction was observed in both episodic and chronic migraine patients, suggesting that erenumab not only helps manage migraines but may also help mitigate the need for additional acute treatment.
Overall, these results highlight the potential benefits of erenumab in addressing not just the frequency of migraines but also reducing dependence on medications traditionally used for acute migraine relief.
Read More